Biocad Will Start Selling The Analogue of Bevacizumab In The Middle Of The Year
Biocad plans to launch the sale of the analogue of anticancer drug called bivacizumab in the second half of 2015. A press release from the manufacturer included the inforamtion that there have been invested more than $10 million in the development of biosimilars of the drug.
The General Direcor of Biocad stated that the production capacity of the company is able to fully cover the needs of patients for bevacizumab in Russia, while the cost of the analogue to the drug will be significantly lower.
"Domestic drug will be manufactured in Russia from substance to redy-for-the-dosage form. As shown by the international clinical trials, the Russian drug is not inferior to imported one in effectiveness and security", - said Dmitry Morozov.
The company stressed that the original bevacizumab produced by Roche, is one of the most expensive drugs purchased by the state. For example, in 2014, as part of a program to provide the population drugs (ONLS) the market of bevacizumab purchases reached 3.2 billion rubles.
Phase III of clical trial of bevacizumab analogue was completed in December 2014. It was found that biosimilar corresponds to the original drug on key indicators, such as efficacy, safety and pharmacokinetics.
- Conditions That May Indicate Cancer
- Green Tea - A secret Weapon Against Oral Cancer
- The U.S Begin To Massively Attack Cancer